250 related articles for article (PubMed ID: 24666588)
1. The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long-term protection from eosinophilic disorders in peanut-sensitized mice.
Dioszeghy V; Mondoulet L; Dhelft V; Ligouis M; Puteaux E; Dupont C; Benhamou PH
Clin Exp Allergy; 2014 Jun; 44(6):867-81. PubMed ID: 24666588
[TBL] [Abstract][Full Text] [Related]
2. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut.
Dioszeghy V; Mondoulet L; Puteaux E; Dhelft V; Ligouis M; Plaquet C; Dupont C; Benhamou PH
Cell Mol Immunol; 2017 Sep; 14(9):770-782. PubMed ID: 27063469
[TBL] [Abstract][Full Text] [Related]
3. Specific epicutaneous immunotherapy prevents sensitization to new allergens in a murine model.
Mondoulet L; Dioszeghy V; Puteaux E; Ligouis M; Dhelft V; Plaquet C; Dupont C; Benhamou PH
J Allergy Clin Immunol; 2015 Jun; 135(6):1546-57.e4. PubMed ID: 25583102
[TBL] [Abstract][Full Text] [Related]
4. CD4(+) CD25(+) T regulatory cells do not transfer oral tolerance to peanut allergens in a mouse model of peanut allergy.
Marcondes Rezende M; Hassing I; Bol-Schoenmakers M; Bleumink R; Boon L; van Bilsen J; Pieters R
Clin Exp Allergy; 2011 Sep; 41(9):1324-33. PubMed ID: 21338425
[TBL] [Abstract][Full Text] [Related]
5. Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice.
Mondoulet L; Dioszeghy V; Larcher T; Ligouis M; Dhelft V; Puteaux E; Cherel Y; Letourneur F; Dupont C; Benhamou PH
PLoS One; 2012; 7(2):e31967. PubMed ID: 22363776
[TBL] [Abstract][Full Text] [Related]
6. Antigen Uptake by Langerhans Cells Is Required for the Induction of Regulatory T Cells and the Acquisition of Tolerance During Epicutaneous Immunotherapy in OVA-Sensitized Mice.
Dioszeghy V; Mondoulet L; Laoubi L; Dhelft V; Plaquet C; Bouzereau A; Dupont C; Sampson H
Front Immunol; 2018; 9():1951. PubMed ID: 30233572
[TBL] [Abstract][Full Text] [Related]
7. Gata3 hypermethylation and Foxp3 hypomethylation are associated with sustained protection and bystander effect following epicutaneous immunotherapy in peanut-sensitized mice.
Mondoulet L; Dioszeghy V; Busato F; Plaquet C; Dhelft V; Bethune K; Leclere L; Daviaud C; Ligouis M; Sampson H; Dupont C; Tost J
Allergy; 2019 Jan; 74(1):152-164. PubMed ID: 29779209
[TBL] [Abstract][Full Text] [Related]
8. Treatment of gastric eosinophilia by epicutaneous immunotherapy in piglets sensitized to peanuts.
Mondoulet L; Kalach N; Dhelft V; Larcher T; Delayre-Orthez C; Benhamou PH; Spergel J; Sampson HA; Dupont C
Clin Exp Allergy; 2017 Dec; 47(12):1640-1647. PubMed ID: 28960628
[TBL] [Abstract][Full Text] [Related]
9. Targeted allergen-specific immunotherapy within the skin improves allergen delivery to induce desensitization to peanut.
Landers JJ; Janczak KW; Shakya AK; Zarnitsyn V; Patel SR; Baker JR; Gill HS; O'Konek JJ
Immunotherapy; 2022 May; 14(7):539-552. PubMed ID: 35196877
[TBL] [Abstract][Full Text] [Related]
10. Food-allergic infants have impaired regulatory T-cell responses following in vivo allergen exposure.
Dang TD; Allen KJ; J Martino D; Koplin JJ; Licciardi PV; Tang ML
Pediatr Allergy Immunol; 2016 Feb; 27(1):35-43. PubMed ID: 26456457
[TBL] [Abstract][Full Text] [Related]
11. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy.
Mondoulet L; Dioszeghy V; Ligouis M; Dhelft V; Dupont C; Benhamou PH
Clin Exp Allergy; 2010 Apr; 40(4):659-67. PubMed ID: 20002446
[TBL] [Abstract][Full Text] [Related]
12. Epicutaneous immunotherapy induces gastrointestinal LAP
Tordesillas L; Mondoulet L; Blazquez AB; Benhamou PH; Sampson HA; Berin MC
J Allergy Clin Immunol; 2017 Jan; 139(1):189-201.e4. PubMed ID: 27417020
[TBL] [Abstract][Full Text] [Related]
13. CD4+CD25+ T cells regulate the intensity of hypersensitivity responses to peanut, but are not decisive in the induction of oral sensitization.
van Wijk F; Wehrens EJ; Nierkens S; Boon L; Kasran A; Pieters R; Knippels LM
Clin Exp Allergy; 2007 Apr; 37(4):572-81. PubMed ID: 17430355
[TBL] [Abstract][Full Text] [Related]
14. Activation of the aryl hydrocarbon receptor suppresses sensitization in a mouse peanut allergy model.
Schulz VJ; Smit JJ; Willemsen KJ; Fiechter D; Hassing I; Bleumink R; Boon L; van den Berg M; van Duursen MB; Pieters RH
Toxicol Sci; 2011 Oct; 123(2):491-500. PubMed ID: 21804081
[TBL] [Abstract][Full Text] [Related]
15. From Skin to Solution: Exploring Epicutaneous Immunotherapy for Peanut Allergy-A Systematic Review and Meta-Analysis.
Banatwala UESS; Nasir MM; Javed R; Ahmed A; Farhan SA; Ajam A
Clin Rev Allergy Immunol; 2024 Apr; 66(2):125-137. PubMed ID: 38526693
[TBL] [Abstract][Full Text] [Related]
16. Epicutaneous peanut patch device for the treatment of peanut allergy.
Langlois A; Graham F; Bégin P
Expert Rev Clin Immunol; 2019 May; 15(5):449-460. PubMed ID: 30864861
[TBL] [Abstract][Full Text] [Related]
17. Activation of the aryl hydrocarbon receptor reduces the number of precursor and effector T cells, but preserves thymic CD4+CD25+Foxp3+ regulatory T cells.
Schulz VJ; Smit JJ; Bol-Schoenmakers M; van Duursen MB; van den Berg M; Pieters RH
Toxicol Lett; 2012 Nov; 215(2):100-9. PubMed ID: 23041608
[TBL] [Abstract][Full Text] [Related]
18. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).
Syed A; Garcia MA; Lyu SC; Bucayu R; Kohli A; Ishida S; Berglund JP; Tsai M; Maecker H; O'Riordan G; Galli SJ; Nadeau KC
J Allergy Clin Immunol; 2014 Feb; 133(2):500-10. PubMed ID: 24636474
[TBL] [Abstract][Full Text] [Related]
19. Update on peanut allergy: Prevention and immunotherapy.
Cook QS; Kim EH
Allergy Asthma Proc; 2019 Jan; 40(1):14-20. PubMed ID: 30582491
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy.
Dupont C; Burks AW; Fleischer DM; Bee KJ; Chainani S; Sampson HA
Expert Rev Clin Immunol; 2024 Jun; 20(6):623-633. PubMed ID: 38323337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
